Related Experiment Video
Updated: Aug 7, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
[Hepatitis C virus antibodies in hemodialyzed patients]
1Institut klinické a experimentální medicíny, Praha.
Insights
Hepatitis C virus (HCV) infection is prevalent in 31% of hemodialysis patients. Newly admitted dialysis patients show a 26% HCV infection rate, with significant variation across centers.
Area of Science:
- Virology
- Infectious Diseases
- Nephrology
Context:
- Hemodialysis is a critical treatment for kidney failure.
- Hepatitis C virus (HCV) poses a significant risk in healthcare settings.
- Dialysis centers require vigilant infection control measures.
Purpose:
- To assess the prevalence of Hepatitis C virus (HCV) antibodies in hemodialysis patients.
- To determine the infection rate among newly admitted dialysis patients.
- To identify variations in HCV prevalence across different dialysis units.
Summary:
- Antibodies against HCV were detected in 31% (196/629) of patients undergoing hemodialysis across 47 centers.
- Among 91 newly admitted dialysis patients, 26% (24/91) tested positive for anti-HCV antibodies.
- The prevalence of anti-HCV antibody carriers ranged widely from 6% to 60% among the studied dialysis units.
Impact:
- Highlights a substantial HCV burden within the hemodialysis population.
- Underscores the need for enhanced screening and prevention strategies in dialysis units.
- Informs public health interventions to mitigate HCV transmission in vulnerable patient groups.
Abstract:
Assessment of antibodies against the hepatitis C virus (HCV) in 629 patients treated by haemodialysis in 47 dialyzation centres revealed the probability of HCV infection in 196 of them, i.e. in 31%. In a group of 91 patients newly admitted for dialysis, antibodies against HCV were found in 24, i.e. in 26%. The percentage of anti-HCV antibody carriers in different dialyzation units varied between 6 nad 60.
